TAKE THIS POLL |
|
|
- Melissa Biggs, Fashion Designer and Former Baywatch Actress, Teams with CSL Behring to Raise Awareness of Alpha-1 Antitr 17 May 2008 13:18 GMT
... and shortness of breath upon exertion, are similar to those of other forms of chronic obstructive pulmonary disease (COPD), Alpha-1 deficiency is significantly underdiagnosed and undertreated. In fact, up to 95 percent of ...
- Melissa Biggs, Fashion Designer and Former Baywatch Actress, Teams with CSL Behring to Raise Awarene 17 May 2008 12:31 GMT
... and shortness of breath upon exertion, are similar to those of other forms of chronic obstructive pulmonary disease (COPD), Alpha-1 deficiency is significantly underdiagnosed and undertreated. In fact, up to 95 percent of ...
- Melissa Biggs, Fashion Designer and Former Baywatch Actress, Teams with CSL Behring to Raise Awareness of Alpha-1 Antitrypsin Deficiency, a Commonly Misdiagnosed Respiratory Disease 17 May 2008 12:31 GMT
... and shortness of breath upon exertion, are similar to those of other forms of chronic obstructive pulmonary disease (COPD), Alpha-1 deficiency is significantly underdiagnosed and undertreated. In fact, up to 95 percent of ...
- Dynavax to Discuss TOLAMBATM Chamber Data; Update 2008 Outlook in Webcast This Morning 17 May 2008 12:30 GMT
... and prevent infectious diseases, allergies, cancer, and chronic inflammatory diseases using versatile, proprietary approaches that alter ... ability of the immune system to fight disease and control chronic inflammation. Our clinical product ... B and C. Our preclinical asthma and COPD program is partnered with AstraZeneca. The NIH ...
- James A. O'Brien Jr. | Insurance executive, 76 17 May 2008 09:09 GMT
... James A. O'Brien Jr. | Insurance executive, 76 ... insurance executive, died Tuesday of complications from chronic obstructive pulmonary disease at Springfield Hospital. Mr. O'Brien ...
- More to outdoors than hunting, fishing 17 May 2008 07:38 GMT
... thermos of coffee and just enjoy. Now that age, arthritis, sinus and a little COPD has caught up to me, I find myself just sitting a lot outdoors. I have ...
- Misdiagnosis letters are re-sent to 4,500 after error 17 May 2008 06:17 GMT
... learn the results. "I've had one lady who had breast cancer and now has COPD (chronic obstructive pulmonary disease). Now she is faced with this recall. She's worried it may take ...
- Depth of MedImmune's Respiratory Disease Research Program Highlighted at Annual Meeting of the American Thoracic Society 17 May 2008 04:41 GMT
... Depth of MedImmune's Respiratory Disease Research Program Highlighted ... potentially address diseases such as asthma and chronic obstructive pulmonary disease." MedImmune research scheduled to be ...
- Pfizer leading: Medicines and people 17 May 2008 04:40 GMT
... a family blighted with the debilitating illness, Chronic Obstructive Pulmonary Disorder. Spiriva, co-promoted with Boehringer Ingleheim, ... Disorder. Spiriva, co-promoted with Boehringer Ingleheim, treats COPD and is now the most prescribed medication ...
- Paul Cessna Vance 17 May 2008 00:28 GMT
... Your browser’s security settings are preventing some features ... 2008, at Iowa Methodist Medical Center of chronic obstructive pulmonary disease and congestive heart failure. A ...
- Evolving Treatments for COPD Emphasizing Innovative Therapies 16 May 2008 22:19 GMT
... Therapeutics and Technologies NASHUA, NH, May 15, 2008 – In terms of patient morbidity, chronic pulmonary obstructive disease (COPD) rivals congestive heart failure as a major healthcare challenge. Primarily smoking-related, COPD is a ...
- Vog expected to ease up 16 May 2008 21:09 GMT
... Volcanic haze blanketed Honolulu for a second day ... severe, Evans said. Those with asthma or chronic obstructive pulmonary disease (bronchitis or emphysema) are in ...
- Street Tips: Dynavax to Discuss TOLAMBA(TM) Chamber Data 16 May 2008 20:59 GMT
... and prevent infectious diseases, allergies, cancer, and chronic inflammatory diseases using versatile, proprietary approaches that alter ... ability of the immune system to fight disease and control chronic inflammation. Our clinical product ... B and C. Our preclinical asthma and COPD program is partnered with AstraZeneca. The NIH ...
- Launches of at least 15 new biologic therapies by 2017 will expand treatment options for Immune and Inflammatory Diseases 16 May 2008 19:53 GMT
... Launches of at least 15 new biologic therapies ... immunomodulators for nine inflammatory diseases-Asthma, Rheumatoid Arthritis, Chronic Obstructive Pulmonary Disease, Psoriasis, Psoriatic Arthritis, Crohn's Disease, ...
- HEATH Asthma 16 May 2008 19:50 GMT
... Last Updated: Tuesday, May 6, 2008 | 2:07 ... is one of the world's most common chronic diseases and is normally more prevalent in ... pneumonia, cystic fibrosis, heart disease and chronic obstructive pulmonary disease should be ruled out before ...
- Clinical Trial Data for Perforomist Inhalation Solution to be Presented at ATS 16 May 2008 19:28 GMT
... details the effects on dyspnea and other COPD symptoms of using Perforomist™ Inhalation Solution, nebulized ... maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and ...
- Theratechnologies Explores Tesamorelin in Growth Hormone Deficient Abdominal Obesity 16 May 2008 17:20 GMT
... increased all with an acceptable safety profile. More specifically, when Theratechnologies investigated wasting in chronic obstructive pulmonary disease (COPD), tesamorelin was also able to show an increase in lean body mass and decreased ...
- Alba Therapeutics Announces the Enrollment and Randomization of the First Patient in the Phase IIb C 16 May 2008 16:51 GMT
... (AT-1001) for the Treatment of Active Celiac Disease Alba Therapeutics Announces the Enrollment and Randomization ... tooth discoloration or loss of enamel, depression, chronic diarrhea or constipation, gas and abdominal pain. The ... such as Celiac disease, Crohn's disease, and Asthma/COPD or acute lung injury. Contact: Wendy Perrow, ...
- Alba Therapeutics Announces the Enrollment and Randomization of the First Patient in the Phase IIb Clinical Trial for La 16 May 2008 15:30 GMT
... (AT-1001) for the Treatment of Active Celiac Disease Alba Therapeutics Announces the Enrollment and Randomization ... tooth discoloration or loss of enamel, depression, chronic diarrhea or constipation, gas and abdominal pain. The ... such as Celiac disease, Crohn's disease, and Asthma/COPD or acute lung injury. Contact: Wendy Perrow, ...
- Dynavax to Discuss TOLAMBA Chamber Data; Update 2008 Outlook in Webcast This Morning 16 May 2008 15:13 GMT
... and prevent infectious diseases, allergies, cancer, and chronic inflammatory diseases using versatile, proprietary approaches that alter ... ability of the immune system to fight disease and control chronic inflammation. Our clinical product ... B and C. Our preclinical asthma and COPD program is partnered with AstraZeneca. The NIH ...
- Clinical Trial Data for Perforomist(TM) Inhalation Solution to be Presented at ATS on May 20, 2008 16 May 2008 14:58 GMT
... fumarate in patients with moderate to severe COPD - NAPA, Calif., May 16 /PRNewswire/ -- ... maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and ...
- Alba Therapeutics Announces the Enrollment and Randomization of the First Patient in the Phase IIb Clinical Trial for Larazotide Acetate (AT-1001) for the Treatment of Active Celiac Disease 16 May 2008 13:56 GMT
... the treatment of patients with active celiac disease (CD). The global multi-center, randomized, double-blind, placebo-controlled ... tooth discoloration or loss of enamel, depression, chronic diarrhea or constipation, gas and abdominal pain. The ... such as Celiac disease, Crohn's disease, and Asthma/COPD or acute lung injury. Contact: Wendy Perrow, ...
- Dynavax TOLAMBA(TM) Chamber Study Misses Primary Endpoint; Company Updates 2008 Financial Outlook 16 May 2008 13:29 GMT
... and prevent infectious diseases, allergies, cancer, and chronic inflammatory diseases using versatile, proprietary approaches that alter ... ability of the immune system to fight disease and control chronic inflammation. Our clinical product ... B and C. Our preclinical asthma and COPD program is partnered with AstraZeneca. The NIH ...
- Dynavax to Discuss TOLAMBA(TM) Chamber Data; Update 2008 Outlook in Webcast This Morning 16 May 2008 12:51 GMT
... and prevent infectious diseases, allergies, cancer, and chronic inflammatory diseases using versatile, proprietary approaches that alter ... ability of the immune system to fight disease and control chronic inflammation. Our clinical product ... B and C. Our preclinical asthma and COPD program is partnered with AstraZeneca. The NIH ...
- Dynavax TOLAMBA Chamber Study Misses Primary Endpoint; Company Updates 2008 Financial Outlook 16 May 2008 12:37 GMT
... and prevent infectious diseases, allergies, cancer, and chronic inflammatory diseases using versatile, proprietary approaches that alter ... ability of the immune system to fight disease and control chronic inflammation. Our clinical product ... B and C. Our preclinical asthma and COPD program is partnered with AstraZeneca. The NIH ...
1 - 25 of 251 next >
News by PR Newswire
|
